TECX
Tectonic Therapeutic, Inc.
Biotechnology
Market Cap$505M
5Y Perf.-88.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
TECX vs RCUS
Revenue, margins, valuation, and 5-year total return — side by side.
RCUS
Arcus Biosciences, Inc.
Biotechnology
Market Cap$2.50B
5Y Perf.-20.9%
TECX vs RCUS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | TECX | RCUS |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $505M | $2.50B |
| Revenue (TTM) | $0.00 | $236M |
| Net Income (TTM) | $-83M | $-369M |
| Gross Margin | — | 90.7% |
| Operating Margin | — | -168.6% |
| Total Debt | $1M | $99M |
| Cash & Equiv. | $254M | $222M |
TECX vs RCUS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
TECX
RCUS
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Tectonic Therapeuti… (TECX) | 100 | 11.1 | -88.9% |
| Arcus Biosciences, … (RCUS) | 100 | 79.1 | -20.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TECX vs RCUS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TECX leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Arcus Biosciences, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
TECX
Tectonic Therapeutic, Inc.
The Income Pick
TECX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.76
- EPS growth -3.1%
- Lower volatility, beta 1.76, Low D/E 0.5%, current ratio 26.63x
Best for: income & stability and growth exposure
RCUS
Arcus Biosciences, Inc.
The Long-Run Compounder
RCUS is the clearest fit if your priority is long-term compounding.
- 45.9% 10Y total return vs TECX's -92.8%
- -4.3% revenue growth vs TECX's -43.4%
- +209.6% vs TECX's +41.6%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | RCUS | -4.3% revenue growth vs TECX's -43.4% |
| Quality / Margins | TECX | 4.3% margin vs RCUS's -156.4% |
| Stability / Safety | TECX | Beta 1.76 vs RCUS's 1.95, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | RCUS | +209.6% vs TECX's +41.6% |
| Efficiency (ROA) | TECX | -30.9% ROA vs RCUS's -35.3%, ROIC -76.5% vs -64.1% |
TECX vs RCUS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
TECX vs RCUS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTECXLAGGINGRCUS
RCUSArcus Biosciences, In…
1leads
TECXTectonic Therapeutic,…
1leads
6 Total Categories
CATEGORYLEADERvs RCUSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
RCUS1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TECX6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
RCUS leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
RCUS and TECX operate at a comparable scale, with $236M and $0 in trailing revenue.
| Metric | TECXTectonic Therapeu… | RCUSArcus Biosciences… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $236M |
| EBITDAEarnings before interest/tax | -$89M | -$391M |
| Net IncomeAfter-tax profit | -$83M | -$369M |
| Free Cash FlowCash after capex | -$66M | -$489M |
| Gross MarginGross profit ÷ Revenue | — | +90.7% |
| Operating MarginEBIT ÷ Revenue | — | -168.6% |
| Net MarginNet income ÷ Revenue | — | -156.4% |
| FCF MarginFCF ÷ Revenue | — | -2.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -39.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -44.1% | +10.5% |
RCUS leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — TECX and RCUS each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | TECXTectonic Therapeu… | RCUSArcus Biosciences… |
|---|---|---|
| Market CapShares × price | $505M | $2.5B |
| Enterprise ValueMkt cap + debt − cash | $252M | $2.4B |
| Trailing P/EPrice ÷ TTM EPS | -6.63x | -7.54x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 10.11x |
| Price / BookPrice ÷ Book value/share | 1.96x | 4.22x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — TECX and RCUS each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
TECX leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
TECX delivers a -32.3% return on equity — every $100 of shareholder capital generates $-32 in annual profit, vs $-69 for RCUS. TECX carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to RCUS's 0.16x. On the Piotroski fundamental quality scale (0–9), TECX scores 4/9 vs RCUS's 0/9, reflecting mixed financial health.
| Metric | TECXTectonic Therapeu… | RCUSArcus Biosciences… |
|---|---|---|
| ROE (TTM)Return on equity | -32.3% | -69.0% |
| ROA (TTM)Return on assets | -30.9% | -35.3% |
| ROICReturn on invested capital | -76.5% | -64.1% |
| ROCEReturn on capital employed | -42.8% | -42.1% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 0 |
| Debt / EquityFinancial leverage | 0.01x | 0.16x |
| Net DebtTotal debt minus cash | -$253M | -$123M |
| Cash & Equiv.Liquid assets | $254M | $222M |
| Total DebtShort + long-term debt | $1M | $99M |
| Interest CoverageEBIT ÷ Interest expense | -1627.77x | -13.38x |
TECX leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — TECX and RCUS each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RCUS five years ago would be worth $8,143 today (with dividends reinvested), compared to $2,604 for TECX. Over the past 12 months, RCUS leads with a +209.6% total return vs TECX's +41.6%. The 3-year compound annual growth rate (CAGR) favors TECX at 46.6% vs RCUS's 7.7% — a key indicator of consistent wealth creation.
| Metric | TECXTectonic Therapeu… | RCUSArcus Biosciences… |
|---|---|---|
| YTD ReturnYear-to-date | +28.5% | +6.5% |
| 1-Year ReturnPast 12 months | +41.6% | +209.6% |
| 3-Year ReturnCumulative with dividends | +215.4% | +24.9% |
| 5-Year ReturnCumulative with dividends | -74.0% | -18.6% |
| 10-Year ReturnCumulative with dividends | -92.8% | +45.9% |
| CAGR (3Y)Annualised 3-year return | +46.6% | +7.7% |
Evenly matched — TECX and RCUS each lead in 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — TECX and RCUS each lead in 1 of 2 comparable metrics.
Risk & Volatility
TECX is the less volatile stock with a 1.76 beta — it tends to amplify market swings less than RCUS's 1.95 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RCUS currently trades 86.3% from its 52-week high vs TECX's 74.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | TECXTectonic Therapeu… | RCUSArcus Biosciences… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.76x | 1.95x |
| 52-Week HighHighest price in past year | $36.02 | $28.72 |
| 52-Week LowLowest price in past year | $14.39 | $7.06 |
| % of 52W HighCurrent price vs 52-week peak | +74.6% | +86.3% |
| RSI (14)Momentum oscillator 0–100 | 50.4 | 60.5 |
| Avg Volume (50D)Average daily shares traded | 249K | 1.2M |
Evenly matched — TECX and RCUS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates TECX as "Buy" and RCUS as "Buy". Consensus price targets imply 151.2% upside for TECX (target: $68) vs 21.0% for RCUS (target: $30).
| Metric | TECXTectonic Therapeu… | RCUSArcus Biosciences… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $67.50 | $30.00 |
| # AnalystsCovering analysts | 4 | 18 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
RCUS leads in 1 of 6 categories (Income & Cash Flow). TECX leads in 1 (Profitability & Efficiency). 3 tied.
Best OverallTectonic Therapeutic, Inc. (TECX)Leads 1 of 6 categories
Loading custom metrics...
TECX vs RCUS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is TECX or RCUS a better buy right now?
Analysts rate Tectonic Therapeutic, Inc.
(TECX) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TECX or RCUS?
Over the past 5 years, Arcus Biosciences, Inc.
(RCUS) delivered a total return of -18. 6%, compared to -74. 0% for Tectonic Therapeutic, Inc. (TECX). Over 10 years, the gap is even starker: RCUS returned +45. 9% versus TECX's -92. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TECX or RCUS?
By beta (market sensitivity over 5 years), Tectonic Therapeutic, Inc.
(TECX) is the lower-risk stock at 1. 76β versus Arcus Biosciences, Inc. 's 1. 95β — meaning RCUS is approximately 11% more volatile than TECX relative to the S&P 500. On balance sheet safety, Tectonic Therapeutic, Inc. (TECX) carries a lower debt/equity ratio of 1% versus 16% for Arcus Biosciences, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — TECX or RCUS?
On earnings-per-share growth, the picture is similar: Tectonic Therapeutic, Inc.
grew EPS -3. 1% year-over-year, compared to -4. 8% for Arcus Biosciences, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — TECX or RCUS?
Tectonic Therapeutic, Inc.
(TECX) is the more profitable company, earning 0. 0% net margin versus -142. 9% for Arcus Biosciences, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TECX leads at 0. 0% versus -156. 3% for RCUS. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — TECX or RCUS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is TECX or RCUS better for a retirement portfolio?
For long-horizon retirement investors, Tectonic Therapeutic, Inc.
(TECX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TECX: -92. 8%, RCUS: +45. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between TECX and RCUS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.